Stay updated on Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedRevision stamp updated from v3.5.3 to v3.5.4, representing a new release version of the site. The change does not modify visible content or study information on the page.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page revision label was updated to v3.5.3, replacing the previous v3.5.2, indicating a backend build update with no changes to study information.SummaryDifference0.1%

- Check36 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed from the page.SummaryDifference0.1%

- Check72 days agoChange Detected- The site revision label was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check101 days agoChange DetectedAdded results metrics (pathologic complete response rate, overall survival, disease-free survival) and counts of drug-related toxicities with posting dates; included investigator/site details (Arsen Osipov, MD; Cedars-Sinai; The University of Texas Health Science Center at San Antonio) and attached the Study Protocol and Statistical Analysis Plan document.SummaryDifference3%

Stay in the know with updates to Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Defactinib in Pancreatic Cancer Clinical Trial page.